ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Core Viewpoint - A class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. for alleged violations of federal securities laws during the Class Period from March 31, 2022, to August 2, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Actinium and its officers made materially false and misleading statements regarding the likelihood of FDA approval for Actinium's Biologics License Application (BLA) for Iomab-B [3]. - Defendants allegedly emphasized positive data from the Phase 3 Sierra trial while downplaying the lack of statistically significant Overall Survival data, misleading investors about the trial's implications for FDA approval [3]. Group 2: Class Action Participation - Investors who purchased Actinium securities during the Class Period are encouraged to join the lawsuit, with a deadline of May 26, 2025, to request lead plaintiff status [4]. - Participation in any recovery does not require serving as lead plaintiff [4]. Group 3: Legal Representation - The law firm Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, meaning they will only collect fees if the lawsuit is successful [5]. - The firm has a history of recovering hundreds of millions of dollars for investors in securities fraud cases [6].